摘要
目的:采用Meta分析方法系统性评价COX-2过表达与浆液性卵巢癌预后的相关性。方法:采用计算机检索中国知网(CNKI)、维普(VIP)、万方(WanFang Data)和PubMed等数据库及会议论文,搜集COX-2的表达与浆液性卵巢癌预后的队列研究,检索时限从建库至2018年11月1日。由2位研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用R3.5.1软件进行分析。结果:共纳入7项研究。Meta分析结果显示:COX-2过表达的患者在总生存期(overall survival,OS;HR=1.57,95%CI:1.26~1.95)、无病生存期(disease-free survival,DFS;HR=2.19,95%CI:1.30~3.68)等方面均差于COX-2低表达的患者。结论:COX-2过表达可能是浆液性卵巢癌患者预后不良的指标。
Objective: To systematically review the prognostic value of COX-2 expression in serous ovarian cancer. Methods: CNKI, VIP, WanFang Data, PubMed databases and Meeting Abstract were searched to collect on the CHM combined with chemotherapy for ovarian cancer from inception to November 1st, 2018. Two reviewers independently screened literature, extracted data and evaluated the risk bias of included studies. Meta-analysis was then performed using R 3.5.1 software. Results: Seven studies were included. Meta-analysis showed that patients with higher COX-2 expression had a poor OS (HR =1.57, 95% CI: 1.26–1.95) and DFS (HR =2.19, 95% CI: 1.30–3.68). Conclusion: The current evidence shows that COX-2 expression had the potential to be a prognostic marker of ovarian cancer.
作者
刘博
柳源
周建国
LIU Bo;LIU Yuan;ZHOU Jianguo(Department of General Practice, Laogang Community Healthcare Service, Shanghai 201302;Department of Healthcare-AssociatedInfection Management, Liaocheng Tumor Hospital, Liaocheng Shandong 252000;Department of Thoracic Oncology, Cancer Hospital,Affiliated Hospital of Zunyi Medical University, Zunyi Guizhou 563099;Department of Thoracic Oncology, Cancer Hospital, SecondAffiliated Hospital of Zunyi Medical University, Zunyi Guizhou 563099, China)
出处
《临床与病理杂志》
2019年第6期1297-1303,共7页
Journal of Clinical and Pathological Research
基金
遵义医学院大学生创新创业训练项目(ZY-201751044,ZYKY-20173830)
贵州省高校口腔重点实验室开放课题(No.6)
贵州省中医药管理局基金(QZYY2017-113)~~
